nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2015-1-66-74nodgo-81Research ArticleОригинальные исследованияВенозные тромбозы у детей со злокачественными новообразованиями (обзор литературы)Venous thromboembolism in children with cancerЖарковПавел АлександровичZharkovP. A.

Россия, 117198, Москва, ул. Саморы Машела, 1

1 Samory Mashela St., Moscow, 117198, Russia

pzharkoff@gmail.comРумянцевА. Г.RumyantsevA. G.

Россия, 117198, Москва, ул. Саморы Машела, 1

1 Samory Mashela St., Moscow, 117198, Russia

НовичковаГ. А.NovichkovaG. A.

Россия, 117198, Москва, ул. Саморы Машела, 1

1 Samory Mashela St., Moscow, 117198, Russia

ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава РоссииРоссияFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaRussian Federation201523052015216674Copyright © Жарков П.А., Румянцев А.Г., Новичкова Г.А., 20152015Жарков П.А., Румянцев А.Г., Новичкова Г.А.Zharkov P.A., Rumyantsev A.G., Novichkova G.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/81

Венозные тромбозы (ВТ) являются частым осложнением терапии злокачественных новообразований (ЗНО) у детей. Возникновение ВТ у ребенка со ЗНО увеличивает длительность лечения, повышает его стоимость, а также негативно влияет на выживаемость и ухудшает качество жизни пациентов. Более глубокое понимание процессов, приводящих к патологическому тромбообразованию у данной группы больных, позволит более эффективно работать в сфере их предупреждения.

Venous thromboembolism (VTE) is a frequent complication in children receiving treatment of cancer. VTE in a child with cancer increases duration of treatment and its cost, may reduce survival rates and affects the quality of life. Better understanding of pathologic processes, causing VTE in children with cancer, will raise an effectiveness of prophylactic approach.

венозный тромбозтромбоэмболиятромбракзлокачественное новообразованиеопухольдетиvenous thrombosisthromboembolismthrombuscancermalignancychildrenReferencesAndrew M., David M., Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251–7.Andrew M., David M., Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251–7.van Ommen C.H., Heijboer H., Büller H.R. et al. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Pediatr 2001;139(5):676–81.van Ommen C.H., Heijboer H., Büller H.R. et al. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Pediatr 2001;139(5):676–81.Nowak-Göttl U., von Kries R., Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76(3):F163–7.Nowak-Göttl U., von Kries R., Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76(3):F163–7.Chan A.K., Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology Am Soc Hematol Educ Program 2012;2012:439–43.Chan A.K., Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology Am Soc Hematol Educ Program 2012;2012:439–43.Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children, s hospitals in the United States from 2001 to 2007. Pediatrics 2009;124(4):1001–8. 6. O,Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children, s hospitals in the United States from 2001 to 2007. Pediatrics 2009;124(4):1001–8. 6. O,Brien S.H., Klima J., Termuhlen A.M., Kelleher K.J. Venous thromboembolism and adolescent and young adult oncology inpatients in US children»s hospitals, 2001 to 2008. J Pediatr 2011;159(1):133–7.Brien S.H., Klima J., Termuhlen A.M., Kelleher K.J. Venous thromboembolism and adolescent and young adult oncology inpatients in US children»s hospitals, 2001 to 2008. J Pediatr 2011;159(1):133–7.Richard H. White the epidemiology of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I4–8.Richard H. White the epidemiology of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I4–8.Bagot C.N., Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008;143(2):180–90.Bagot C.N., Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008;143(2):180–90.Blann A.D., Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract 2011;2011:394740.Blann A.D., Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract 2011;2011:394740.Долгов В.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. Тверь: Триада, 2005. [Dolgov V.V., Svirin P.V. Laboratory diagnosis of disorders of hemostasis. Tver: Triada, 2005. (In Russ.)].Долгов В.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. Тверь: Триада, 2005. [Dolgov V.V., Svirin P.V. Laboratory diagnosis of disorders of hemostasis. Tver: Triada, 2005. (In Russ.)].Hoffman R., Haim N., Brenner B. Cancer and thrombosis revisited. Blood Rev 2001;15(2):61–7.Hoffman R., Haim N., Brenner B. Cancer and thrombosis revisited. Blood Rev 2001;15(2):61–7.Oleksowicz L., Bhagwati N., DeLeon-Fernandez M. Deficient activity of von Willebrand»s factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999;59(9):2244–50.Oleksowicz L., Bhagwati N., DeLeon-Fernandez M. Deficient activity of von Willebrand»s factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999;59(9):2244–50.Kakkar A.K., DeRuvo N., Chinswangwatanakul V. Tebbutt Set al. Extrinsic pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346(8981):1004–5.Kakkar A.K., DeRuvo N., Chinswangwatanakul V. Tebbutt Set al. Extrinsic pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346(8981):1004–5.Rickles F.R., Brenner B. Tissue factor and cancer. Semin Thromb Hemost 2008;34(2):143–5.Rickles F.R., Brenner B. Tissue factor and cancer. Semin Thromb Hemost 2008;34(2):143–5.Mielicki W.P., Tenderenda M., Rutkowski P., Chojnowski K. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett 1999;146(1):61–6.Mielicki W.P., Tenderenda M., Rutkowski P., Chojnowski K. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett 1999;146(1):61–6.Prandoni P., Villalta S., Bagatella P. et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82(4):423–8.Prandoni P., Villalta S., Bagatella P. et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82(4):423–8.Young A., Chapman O., Connor C. et al. Thrombosis and cancer. Nat Rev Clin Oncol 2012;9(8):437–49.Young A., Chapman O., Connor C. et al. Thrombosis and cancer. Nat Rev Clin Oncol 2012;9(8):437–49.Mitchell L., Andrew M., Hanna K. et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90(2):235–44.Mitchell L., Andrew M., Hanna K. et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90(2):235–44.Athale U.H., Chan A.K. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003;111(3):125–31.Athale U.H., Chan A.K. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003;111(3):125–31.Caruso V., Iacoviello L., Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108(7): 2216–22.Caruso V., Iacoviello L., Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108(7): 2216–22.Athale U., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7.Athale U., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7.Grace R.F., Dahlberg S.E., Neuberg D. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Consortium protocols. Br J Haematol 2011;152(4):452–9.Grace R.F., Dahlberg S.E., Neuberg D. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Consortium protocols. Br J Haematol 2011;152(4):452–9.Wermes C., von Depka Prondzinski M., Lichtinghagen R. et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158 (Suppl 3):S143–6.Wermes C., von Depka Prondzinski M., Lichtinghagen R. et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158 (Suppl 3):S143–6.Athale U.H., Siciliano S.A., Crowther M. et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129(6):803–10.Athale U.H., Siciliano S.A., Crowther M. et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129(6):803–10.Athale U.H., Nagel K., Khan A.A., Chan A.K. Thromboembolism in children with lymphoma. Thromb Res 2008;122(4):459–65.Athale U.H., Nagel K., Khan A.A., Chan A.K. Thromboembolism in children with lymphoma. Thromb Res 2008;122(4):459–65.Tabori U., Beni-Adani L., Dvir R. et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004;43(6):633–6.Tabori U., Beni-Adani L., Dvir R. et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004;43(6):633–6.Deitcher S.R., Gajjar A., Kun L., Heideman R.L. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004;145(6):848–50.Deitcher S.R., Gajjar A., Kun L., Heideman R.L. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004;145(6):848–50.Al-Mateen M., Hood M., Trippel D. et al. Cerebral embolism from atrial myxoma in pediatric patients. Pediatrics 2003;112(2):e162–7.Al-Mateen M., Hood M., Trippel D. et al. Cerebral embolism from atrial myxoma in pediatric patients. Pediatrics 2003;112(2):e162–7.Paz-Priel I., Long L., Helman L.J. et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007;25(12):1519–24.Paz-Priel I., Long L., Helman L.J. et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007;25(12):1519–24.Lipay N.V., Zmitrovich A.I., Aleinikova O.V. Epidemiology of venous thromboembolism in children with malignant diseases: a single-center study of the Belarusian Center for Pediatric Oncology and Hematology. Thromb Res 2011;128(2):130–4.Lipay N.V., Zmitrovich A.I., Aleinikova O.V. Epidemiology of venous thromboembolism in children with malignant diseases: a single-center study of the Belarusian Center for Pediatric Oncology and Hematology. Thromb Res 2011;128(2):130–4.Pui C.H., Campana D., Pei D. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Eng J Med 2009;360(26):2730–41.Pui C.H., Campana D., Pei D. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Eng J Med 2009;360(26):2730–41.Möricke A., Reiter A., Zimmermann M. et al. Risk-adjusted therapy for acute lymphoblastic leukemia can reduce therapy burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111(9):4477–89.Möricke A., Reiter A., Zimmermann M. et al. Risk-adjusted therapy for acute lymphoblastic leukemia can reduce therapy burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111(9):4477–89.Audino A.N., Yeager N.D., Asti L. et al. Length of stay and treatment-related complications are similar in pediatric and AYA patients with bone sarcoma in United States Children, s Hospitals. Pediatr Blood Cancer 2013;60(3):415–9.Audino A.N., Yeager N.D., Asti L. et al. Length of stay and treatment-related complications are similar in pediatric and AYA patients with bone sarcoma in United States Children, s Hospitals. Pediatr Blood Cancer 2013;60(3):415–9.Thodiyil P.A., Kakkar A.K. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002;87(6):1076–7.Thodiyil P.A., Kakkar A.K. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002;87(6):1076–7.Chew H.K., Wun T., Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458–64.Chew H.K., Wun T., Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458–64.Athale U. Thrombosis in pediatric cancer: identifying the risk factors to improve care. Expert Rev Hematol 2013;6(5):599–609.Athale U. Thrombosis in pediatric cancer: identifying the risk factors to improve care. Expert Rev Hematol 2013;6(5):599–609.Hernández-Espinosa D., Miñano A., Martínez C. et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006;169(1):142–53.Hernández-Espinosa D., Miñano A., Martínez C. et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006;169(1):142–53.Albayrak M., Gürsel T., Kaya Z., Koçak U. Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia. Clin Appl Thromb Hemost 2013;19(6):644–51.Albayrak M., Gürsel T., Kaya Z., Koçak U. Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia. Clin Appl Thromb Hemost 2013;19(6):644–51.Jalali M.T., Khosravi M., Keikhaei B. et al. Evaluation of plasma activity level of anticoagulant proteins in patients with acute lymphoblastic leukemia in Shafa hospital Ahwaz 2010. Eur Rev Med Pharmacol Sci 2012;16(8):1045–51.Jalali M.T., Khosravi M., Keikhaei B. et al. Evaluation of plasma activity level of anticoagulant proteins in patients with acute lymphoblastic leukemia in Shafa hospital Ahwaz 2010. Eur Rev Med Pharmacol Sci 2012;16(8):1045–51.Appel I.M., Hop W.C., van Kessel-Bakvis C. et al. L-asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008;100(2):330–7.Appel I.M., Hop W.C., van Kessel-Bakvis C. et al. L-asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008;100(2):330–7.Dixit A., Kannan M., Mahapatra M. et al. Roles of protein C, protein S, and antithrombin III in acute leukemia. Am J Hematol 2006;81(3):171–4.Dixit A., Kannan M., Mahapatra M. et al. Roles of protein C, protein S, and antithrombin III in acute leukemia. Am J Hematol 2006;81(3):171–4.Kuhle S., Lau A., Bajzar L. et. al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol 2006;134(5):526–31.Kuhle S., Lau A., Bajzar L. et. al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol 2006;134(5):526–31.Oztürk G., Ozsoylu S., Gürsel T. Effects of methylprednisolone on FVIII: C and vWF levels. Eur J Haematol 1994;53(2):119–20.Oztürk G., Ozsoylu S., Gürsel T. Effects of methylprednisolone on FVIII: C and vWF levels. Eur J Haematol 1994;53(2):119–20.Sartori M.T., Rigotti P., Marchini F. et al. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy. Transplantation 2003;75(7):994–8.Sartori M.T., Rigotti P., Marchini F. et al. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy. Transplantation 2003;75(7):994–8.Mills P.J., Parker B., Jones V. et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin Cancer Res 2004;10(15):4998–5003.Mills P.J., Parker B., Jones V. et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin Cancer Res 2004;10(15):4998–5003.Walsh J., Wheeler H.R., Geczy C.L. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992;81(4):480–8.Walsh J., Wheeler H.R., Geczy C.L. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992;81(4):480–8.Boles J.C., Williams J.C., Hollingsworth R.M. et al. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphotidylserine exposure and tissue factor activity. Thromb Res 2012;129(2):197–203.Boles J.C., Williams J.C., Hollingsworth R.M. et al. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphotidylserine exposure and tissue factor activity. Thromb Res 2012;129(2):197–203.Glaser D.W., Medeiros D., Rollins N., Buchanan G.R. Catheter-related thrombosis in children with cancer. J Pediatr 2001;138(2):255–9.Glaser D.W., Medeiros D., Rollins N., Buchanan G.R. Catheter-related thrombosis in children with cancer. J Pediatr 2001;138(2):255–9.Revel-Vilk S., Yacobovich J., Tamary H. et al. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer 2010;116(17):4197–205.Revel-Vilk S., Yacobovich J., Tamary H. et al. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer 2010;116(17):4197–205.Journeycake J.M., Buchanan G.R. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 2006;24(28): 4575–80.Journeycake J.M., Buchanan G.R. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 2006;24(28): 4575–80.Nowak-Göttl U., Wermes C., Junker R. et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93(5):1595–9.Nowak-Göttl U., Wermes C., Junker R. et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93(5):1595–9.Knöfler R., Siegert E., Lauterbach I. et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy – impact of central venous lines.Eur J Pediatr 1999;158(Suppl 3):S147–50.Knöfler R., Siegert E., Lauterbach I. et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy – impact of central venous lines.Eur J Pediatr 1999;158(Suppl 3):S147–50.Nowak-Göttl U., Kenet G., Mitchell L.G. Thrombosis in childhood acute lymphoblastic leukemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009;22(1):103–14.Nowak-Göttl U., Kenet G., Mitchell L.G. Thrombosis in childhood acute lymphoblastic leukemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009;22(1):103–14.Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902–7.Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902–7.Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24): 5377–82.Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24): 5377–82.Mitchell L., Lambers M., Flege S. et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010;115(24):4999–5004.Mitchell L., Lambers M., Flege S. et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010;115(24):4999–5004.Abbott L.S., Deevska M., Fernandez C.V. et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009;114(25):5146–51.Abbott L.S., Deevska M., Fernandez C.V. et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009;114(25):5146–51.Elhasid R., Lanir N., Sharon R. et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001;12(5):367–70.Elhasid R., Lanir N., Sharon R. et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001;12(5):367–70.Harlev D., Zaidman I., Sarig G. et al. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thromb Res 2010;126(2):93–7.Harlev D., Zaidman I., Sarig G. et al. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thromb Res 2010;126(2):93–7.Meister B., Kropshofer G., Klein-Franke A. et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50(2): 298–303.Meister B., Kropshofer G., Klein-Franke A. et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50(2): 298–303.

The authors declare that there are no conflicts of interest present.